https://staging.pauljanssenfuturelab.eu/topic/test-topic-1/2016-10-13T18:35:02+02:00https://staging.pauljanssenfuturelab.eu/topic/test-topic-2/2016-09-30T14:24:07+02:00https://staging.pauljanssenfuturelab.eu/topic/test-topic-3/2016-10-05T16:25:05+02:00https://staging.pauljanssenfuturelab.eu/topic/test-topic-4/2016-10-05T16:40:45+02:00https://staging.pauljanssenfuturelab.eu/topic/test-topic-5/2016-10-08T14:27:23+02:00https://staging.pauljanssenfuturelab.eu/topic/test-topic-bij-testles-1/2016-10-08T15:01:12+02:00https://staging.pauljanssenfuturelab.eu/topic/test-topic-2-bij-course-2/2016-10-09T16:45:24+02:00https://staging.pauljanssenfuturelab.eu/topic/week-1-learning-objectives/2018-03-05T10:38:31+02:00https://staging.pauljanssenfuturelab.eu/topic/217/2017-10-11T11:23:58+02:00https://staging.pauljanssenfuturelab.eu/topic/real-options/2021-03-04T17:57:50+02:00https://staging.pauljanssenfuturelab.eu/topic/1/2016-10-17T20:42:33+02:00https://staging.pauljanssenfuturelab.eu/topic/week-2-learning-objectives/2016-11-17T15:56:39+02:00https://staging.pauljanssenfuturelab.eu/topic/clinical-development-in-perspective/2017-08-23T10:56:54+02:00https://staging.pauljanssenfuturelab.eu/topic/2/2016-10-13T13:28:14+02:00https://staging.pauljanssenfuturelab.eu/topic/3/2016-10-13T13:28:28+02:00https://staging.pauljanssenfuturelab.eu/topic/target-optimization/2017-08-23T10:59:46+02:00https://staging.pauljanssenfuturelab.eu/topic/process-optimization/2017-08-23T11:11:56+02:00https://staging.pauljanssenfuturelab.eu/topic/classical-development-phases/2021-03-04T18:02:39+02:00https://staging.pauljanssenfuturelab.eu/topic/net-present-value/2017-08-22T15:37:33+02:00https://staging.pauljanssenfuturelab.eu/topic/real-options-model-for-linear-development/2019-10-07T12:48:04+02:00https://staging.pauljanssenfuturelab.eu/topic/weekly-summary/2017-08-23T10:43:29+02:00https://staging.pauljanssenfuturelab.eu/topic/week-3-learning-objectives/2017-08-24T14:29:14+02:00https://staging.pauljanssenfuturelab.eu/topic/modern-drug-development/2021-03-24T12:32:39+02:00https://staging.pauljanssenfuturelab.eu/topic/from-phases-to-questions/2019-10-07T13:28:36+02:00https://staging.pauljanssenfuturelab.eu/topic/emas-perception-on-question-based-development/2020-01-10T17:26:58+02:00https://staging.pauljanssenfuturelab.eu/topic/tutorial-question-optimization-calculator/2017-04-20T13:50:29+02:00https://staging.pauljanssenfuturelab.eu/topic/qoc-story-example/2017-11-02T10:10:09+02:00https://staging.pauljanssenfuturelab.eu/topic/week-3-summary/2017-03-27T13:59:33+02:00https://staging.pauljanssenfuturelab.eu/topic/week-4-learning-objectives/2017-03-27T14:12:50+02:00https://staging.pauljanssenfuturelab.eu/topic/week-5-learning-objectives/2017-08-28T13:37:14+02:00https://staging.pauljanssenfuturelab.eu/topic/from-questions-to-development-outline/2017-08-28T11:49:01+02:00https://staging.pauljanssenfuturelab.eu/topic/case-1-developing-a-novel-intervention-for-a-life-threatening-disease-using-probiotics/2017-02-02T14:32:39+02:00https://staging.pauljanssenfuturelab.eu/topic/personal-case/2017-10-11T11:39:09+02:00https://staging.pauljanssenfuturelab.eu/topic/weekly-summary-2/2017-08-23T10:38:21+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-1-les-1-course-4/2016-11-03T10:50:45+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-2-les-1-course-4/2016-10-20T13:54:05+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-3-les-1-course-4/2016-10-20T13:20:58+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-4-les-1-course-4/2016-10-28T17:20:37+02:00https://staging.pauljanssenfuturelab.eu/topic/modern-device-development/2017-08-23T11:31:44+02:00https://staging.pauljanssenfuturelab.eu/topic/modern-medical-nutrition-development/2021-03-24T12:38:40+02:00https://staging.pauljanssenfuturelab.eu/topic/a-history-of-drug-development/2021-03-24T12:36:45+02:00https://staging.pauljanssenfuturelab.eu/topic/classical-development-phases-2/2016-11-18T15:15:04+02:00https://staging.pauljanssenfuturelab.eu/topic/questions-optimizing-calculator/2017-11-02T18:08:08+02:00https://staging.pauljanssenfuturelab.eu/topic/case-1/2020-10-07T12:37:23+02:00https://staging.pauljanssenfuturelab.eu/topic/case-1-2/2017-08-28T12:13:41+02:00https://staging.pauljanssenfuturelab.eu/topic/case-1-3/2017-08-28T12:15:13+02:00https://staging.pauljanssenfuturelab.eu/topic/week-4-summary/2017-08-28T13:32:33+02:00https://staging.pauljanssenfuturelab.eu/topic/week-5-summary/2017-08-29T09:50:00+02:00https://staging.pauljanssenfuturelab.eu/topic/question/2016-11-24T17:13:17+02:00https://staging.pauljanssenfuturelab.eu/topic/case-2/2017-08-29T09:38:15+02:00https://staging.pauljanssenfuturelab.eu/topic/case-2-2/2020-10-07T12:38:11+02:00https://staging.pauljanssenfuturelab.eu/topic/case-2-development-outline/2017-03-27T15:41:13+02:00https://staging.pauljanssenfuturelab.eu/topic/case-2-what-really-happened/2017-08-29T09:32:43+02:00https://staging.pauljanssenfuturelab.eu/topic/case-3-introduction/2017-08-29T09:40:52+02:00https://staging.pauljanssenfuturelab.eu/topic/case-3-qoc/2020-10-07T12:38:52+02:00https://staging.pauljanssenfuturelab.eu/topic/case-3-development-outline/2017-08-29T09:44:34+02:00https://staging.pauljanssenfuturelab.eu/topic/case-3-what-really-happened/2019-10-07T14:17:29+02:00https://staging.pauljanssenfuturelab.eu/topic/case-4-introduction/2017-03-13T15:55:09+02:00https://staging.pauljanssenfuturelab.eu/topic/case-4-qoc/2020-10-07T12:36:12+02:00https://staging.pauljanssenfuturelab.eu/topic/case-4-development-outline/2020-10-02T13:32:10+02:00https://staging.pauljanssenfuturelab.eu/topic/case-4-what-really-happened-2/2019-04-17T09:59:24+02:00https://staging.pauljanssenfuturelab.eu/topic/real-options-other-industries/2020-01-10T17:20:14+02:00https://staging.pauljanssenfuturelab.eu/topic/real-options-perceived-hurdles/2021-01-22T13:41:30+02:00https://staging.pauljanssenfuturelab.eu/topic/attrition-rates-in-pharmaceutical-development/2021-01-22T13:40:02+02:00https://staging.pauljanssenfuturelab.eu/topic/monty-hall-explained/2017-08-22T15:34:39+02:00https://staging.pauljanssenfuturelab.eu/topic/using-questions-in-development/2017-08-24T14:41:40+02:00https://staging.pauljanssenfuturelab.eu/topic/developing-prototypes/2021-01-22T13:42:14+02:00https://staging.pauljanssenfuturelab.eu/topic/real-options-for-the-development-of-medical-devices/2021-01-22T13:41:39+02:00https://staging.pauljanssenfuturelab.eu/topic/pharma-nutrition-interface/2021-01-22T13:41:46+02:00https://staging.pauljanssenfuturelab.eu/topic/putting-a-price-on-biotech/2021-01-22T13:41:55+02:00https://staging.pauljanssenfuturelab.eu/topic/dispute-putting-a-price-on-biotech/2021-01-22T13:42:08+02:00https://staging.pauljanssenfuturelab.eu/topic/episode-5-option-a/2020-07-10T11:50:17+02:00https://staging.pauljanssenfuturelab.eu/topic/episode-5-option-b/2020-07-10T11:50:58+02:00https://staging.pauljanssenfuturelab.eu/topic/feedback-week-5/2019-10-07T14:22:07+02:00https://staging.pauljanssenfuturelab.eu/topic/case-3-interview-with-medtronics-cso-rick-kuntz/2017-03-20T16:26:03+02:00https://staging.pauljanssenfuturelab.eu/topic/net-present-value-and-risk-adjustment/2020-01-10T17:20:59+02:00https://staging.pauljanssenfuturelab.eu/topic/npv-rnpv-real-options/2019-10-17T09:52:01+02:00https://staging.pauljanssenfuturelab.eu/topic/learning-and-confirming/2021-01-22T13:42:32+02:00https://staging.pauljanssenfuturelab.eu/topic/case-2-letters-lancet/2021-01-22T13:42:47+02:00https://staging.pauljanssenfuturelab.eu/topic/case-2-study-article/2021-01-22T13:42:39+02:00https://staging.pauljanssenfuturelab.eu/topic/history-patent-system/2017-11-27T12:30:23+02:00https://staging.pauljanssenfuturelab.eu/topic/protecting-drugs-devices/2017-09-21T21:28:45+02:00https://staging.pauljanssenfuturelab.eu/topic/protecting-medical-devices-usa-europe/2017-09-21T17:55:42+02:00https://staging.pauljanssenfuturelab.eu/topic/towards-unitary-patent-europe/2017-07-19T10:47:30+02:00https://staging.pauljanssenfuturelab.eu/topic/building-patent-portfolio/2019-05-22T16:14:15+02:00https://staging.pauljanssenfuturelab.eu/topic/timelines-and-costs-in-developing-a-patent-portfolio/2019-09-19T15:00:15+02:00https://staging.pauljanssenfuturelab.eu/topic/poc-practising-examples/2019-04-04T10:18:56+02:00https://staging.pauljanssenfuturelab.eu/topic/poc-exercise-2/2019-09-30T11:27:42+02:00https://staging.pauljanssenfuturelab.eu/topic/commercialisation-of-ip/2020-09-15T09:30:14+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-procedures-europe-usa/2019-10-16T15:15:14+02:00https://staging.pauljanssenfuturelab.eu/topic/protecting-drugs/2017-11-27T12:35:05+02:00https://staging.pauljanssenfuturelab.eu/topic/negotiating-appropriate-compensation/2021-01-22T13:31:35+02:00https://staging.pauljanssenfuturelab.eu/topic/patenting-in-the-usa/2019-02-07T17:10:43+02:00https://staging.pauljanssenfuturelab.eu/topic/futurelab-talk-maurits-westerik/2021-04-14T11:38:50+02:00https://staging.pauljanssenfuturelab.eu/topic/830-1200/2019-05-17T12:14:48+02:00https://staging.pauljanssenfuturelab.eu/topic/1300-1730/2017-07-03T15:03:23+02:00https://staging.pauljanssenfuturelab.eu/topic/welcome-dinner/2017-07-03T16:18:30+02:00https://staging.pauljanssenfuturelab.eu/topic/boating-and-dinner/2017-08-09T14:17:28+02:00https://staging.pauljanssenfuturelab.eu/topic/legislation-medical-research-involving-human-subjects-netherlands/2021-01-22T14:38:16+02:00https://staging.pauljanssenfuturelab.eu/topic/selecting-right-reviewing-committee/2021-05-20T10:11:12+02:00https://staging.pauljanssenfuturelab.eu/topic/review-process-clinical-research-involving-investigational-medicinal-products/2021-05-20T10:19:01+02:00https://staging.pauljanssenfuturelab.eu/topic/the-tasks-of-the-ccmo/2021-05-20T10:40:02+02:00https://staging.pauljanssenfuturelab.eu/topic/the-accredited-mrec/2021-05-26T08:51:41+02:00https://staging.pauljanssenfuturelab.eu/topic/about-this-course/2021-05-20T10:38:03+02:00https://staging.pauljanssenfuturelab.eu/topic/clinical-research-netherlands-feedback/2018-03-08T17:08:48+02:00https://staging.pauljanssenfuturelab.eu/topic/830-1230-roche-vemurafenib/2019-05-28T11:45:04+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-roche-vemurafenib/2018-05-22T15:56:19+02:00https://staging.pauljanssenfuturelab.eu/topic/ib-roche-vemurafenib/2017-08-16T15:42:39+02:00https://staging.pauljanssenfuturelab.eu/topic/additional-required-reading/2017-08-09T17:12:21+02:00https://staging.pauljanssenfuturelab.eu/topic/nature-medicine-2011-targeting-raf/2017-08-09T17:24:23+02:00https://staging.pauljanssenfuturelab.eu/topic/nejm-2010-inhibition-mutated-activated-braf-metastatic-melanoma/2017-08-09T17:40:56+02:00https://staging.pauljanssenfuturelab.eu/topic/j-clin-oncol-2011-dissecting-therapeutic-resistance-raf-inhibition/2017-08-10T08:45:30+02:00https://staging.pauljanssenfuturelab.eu/topic/program-case-study-gm-csf-antibody/2017-09-06T16:49:39+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-gm-csf-antibody/2017-09-06T16:08:04+02:00https://staging.pauljanssenfuturelab.eu/topic/expert-rev-clin-immunol-2015-gm-csf-target-inflammatoryautoimmune-disease/2017-08-10T14:07:00+02:00https://staging.pauljanssenfuturelab.eu/topic/mol-immunol-2013-gm-csf-therapeutic-target-inflammatory-diseases/2017-08-10T14:17:10+02:00https://staging.pauljanssenfuturelab.eu/topic/ann-rheum-dis-2015-mor103-treatment-patients-moderate-rheumatoid-arthritis/2017-08-10T14:19:16+02:00https://staging.pauljanssenfuturelab.eu/topic/program/2019-04-24T11:09:34+02:00https://staging.pauljanssenfuturelab.eu/topic/program-2/2019-05-28T11:43:30+02:00https://staging.pauljanssenfuturelab.eu/topic/program-3/2019-05-30T12:37:34+02:00https://staging.pauljanssenfuturelab.eu/topic/program-4/2019-06-02T20:12:21+02:00https://staging.pauljanssenfuturelab.eu/topic/program-5/2017-09-06T16:53:13+02:00https://staging.pauljanssenfuturelab.eu/topic/program-6/2017-08-22T17:19:30+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study/2021-02-25T10:40:10+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-2/2021-02-25T10:25:53+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-3/2017-08-28T16:24:56+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-4/2021-02-25T10:35:07+02:00https://staging.pauljanssenfuturelab.eu/topic/ib-immunothera-it53/2021-02-25T10:26:33+02:00https://staging.pauljanssenfuturelab.eu/topic/emergency-hospital-bbc-documentary/2019-04-29T14:57:35+02:00https://staging.pauljanssenfuturelab.eu/topic/template-research-protocol/2019-05-29T12:40:28+02:00https://staging.pauljanssenfuturelab.eu/topic/ib-janssen-bedaquiline/2021-02-25T10:41:31+02:00https://staging.pauljanssenfuturelab.eu/topic/science-2005-bedaquiline-and-supplement/2021-02-25T10:42:47+02:00https://staging.pauljanssenfuturelab.eu/topic/science-2005-tb-new-target-science/2021-02-25T10:45:29+02:00https://staging.pauljanssenfuturelab.eu/topic/science-2004-new-tb-drug-promises-shorter-simpler-treatment/2021-02-25T10:43:56+02:00https://staging.pauljanssenfuturelab.eu/topic/world-j-pediatr-congenit-heart-surg-2016-current-status-tissue-engineering-heart-valve/2017-08-28T10:11:04+02:00https://staging.pauljanssenfuturelab.eu/topic/ann-biomed-eng-2016-improved-geometry-decellularized-tissue-engineered-heart-valves-prevent-leaflet-retraction/2017-08-29T13:01:48+02:00https://staging.pauljanssenfuturelab.eu/topic/biomaterials-2017-situ-heart-valve-tissue-engineering-sheep-study/2017-08-29T13:02:05+02:00https://staging.pauljanssenfuturelab.eu/topic/biomateriaal-2016-bioative-factors-scaffold/2017-08-29T13:02:18+02:00https://staging.pauljanssenfuturelab.eu/topic/fda-guidance-industry-2005-estimating-maximum-safe-starting-dose/2021-02-25T10:27:34+02:00https://staging.pauljanssenfuturelab.eu/topic/ema-guideline-2007-strategies-identify-mitigate-risks-first-human-clinical-trials/2021-02-25T10:28:19+02:00https://staging.pauljanssenfuturelab.eu/topic/eur-heart-j-2011-injectable-living-marrow-stromal-cell-based-autologous-tissue-engineered-heart-valves-first-experiences-one-step-intervention-primates/2017-08-29T12:21:04+02:00https://staging.pauljanssenfuturelab.eu/topic/interview-paul-stoffels-development-bedaquiline/2019-05-01T12:32:09+02:00https://staging.pauljanssenfuturelab.eu/topic/preparatory-assignment/2019-05-17T12:20:47+02:00https://staging.pauljanssenfuturelab.eu/topic/investigators-brochure-reef-biotech-rb3285/2021-02-25T10:38:24+02:00https://staging.pauljanssenfuturelab.eu/topic/on-campus-feedback/2019-06-06T17:19:58+02:00https://staging.pauljanssenfuturelab.eu/topic/campus-extended-feedback/2017-08-31T17:10:11+02:00https://staging.pauljanssenfuturelab.eu/topic/bjcp-2015-extraordinary-development-route-antibody-tgn1412/2019-04-29T14:07:08+02:00https://staging.pauljanssenfuturelab.eu/topic/eur-j-immunol-2014-selective-activation-human-treg-cells-tgn1412-tab08/2019-04-29T14:07:25+02:00https://staging.pauljanssenfuturelab.eu/topic/lancet-2006-lessons-tgn1412/2019-04-29T14:58:01+02:00https://staging.pauljanssenfuturelab.eu/topic/nejm-2006-cytokine-storm-phase-1-trial-anti-cd28-monoclonal-antibody-tgn1412/2019-04-29T14:58:28+02:00https://staging.pauljanssenfuturelab.eu/topic/xenobiotica-2007-human-dose-first-man/2019-04-29T14:58:37+02:00https://staging.pauljanssenfuturelab.eu/topic/questions-list-order/2017-09-07T11:24:07+02:00https://staging.pauljanssenfuturelab.eu/topic/patenting-commercialization-filgotinib/2019-01-28T23:04:26+02:00https://staging.pauljanssenfuturelab.eu/topic/case-1-filgotinib/2019-05-24T12:32:03+02:00https://staging.pauljanssenfuturelab.eu/topic/filgotinib-really-happened/2019-05-24T12:32:45+02:00https://staging.pauljanssenfuturelab.eu/topic/case-merus-patent-portfolio/2019-05-20T16:17:37+02:00https://staging.pauljanssenfuturelab.eu/topic/case-merus-actual-situation/2019-04-04T10:18:57+02:00https://staging.pauljanssenfuturelab.eu/topic/campus-extended-powerpoints/2017-09-21T20:45:29+02:00https://staging.pauljanssenfuturelab.eu/topic/summary-of-the-qoc-exercises/2020-01-09T17:49:10+02:00https://staging.pauljanssenfuturelab.eu/topic/case-example-site-action/2018-02-21T15:11:30+02:00https://staging.pauljanssenfuturelab.eu/topic/applying-site-action-methodology/2017-11-06T10:55:30+02:00https://staging.pauljanssenfuturelab.eu/topic/methodology-site-action-question/2017-11-06T10:57:09+02:00https://staging.pauljanssenfuturelab.eu/topic/self-assessment-questions-article/2017-11-06T10:58:11+02:00https://staging.pauljanssenfuturelab.eu/topic/drug-regimen-determination-example/2017-11-06T10:59:39+02:00https://staging.pauljanssenfuturelab.eu/topic/volume-distribution-elimination-metabolism-overview/2017-11-06T11:03:15+02:00https://staging.pauljanssenfuturelab.eu/topic/related-topics-depth-links/2017-11-06T11:05:39+02:00https://staging.pauljanssenfuturelab.eu/topic/self-assessment-questions-article-2/2017-11-06T11:06:47+02:00https://staging.pauljanssenfuturelab.eu/topic/example-impact-different-route-novel-interventions/2017-11-06T11:07:31+02:00https://staging.pauljanssenfuturelab.eu/topic/routes-of-administration/2017-11-06T11:08:18+02:00https://staging.pauljanssenfuturelab.eu/topic/route-administration-adme-impact-novel-treatment-development/2017-11-06T11:09:19+02:00https://staging.pauljanssenfuturelab.eu/topic/learning-objectives-explaining-pk-what-the-body-does-to-the-drug/2017-11-06T11:10:26+02:00https://staging.pauljanssenfuturelab.eu/topic/applying-methodology-different-types-interventions/2017-11-06T11:15:40+02:00https://staging.pauljanssenfuturelab.eu/topic/methodology-pharmacology-question/2019-01-28T14:42:08+02:00https://staging.pauljanssenfuturelab.eu/topic/self-assessment-questions-article-3/2017-11-06T11:17:38+02:00https://staging.pauljanssenfuturelab.eu/topic/example-developing-novel-mechanism-action/2017-11-06T11:18:28+02:00https://staging.pauljanssenfuturelab.eu/topic/signalling-pathways-overview/2017-11-06T11:19:27+02:00https://staging.pauljanssenfuturelab.eu/topic/related-topics-depth-links-2/2017-11-06T11:20:22+02:00https://staging.pauljanssenfuturelab.eu/topic/self-assessment-questions-article-4/2017-11-06T11:21:06+02:00https://staging.pauljanssenfuturelab.eu/topic/example-impact-pharmacology-specific-issue/2017-11-06T11:22:05+02:00https://staging.pauljanssenfuturelab.eu/topic/overview-animation-target-ligands-binding-interaction/2017-11-06T11:22:49+02:00https://staging.pauljanssenfuturelab.eu/topic/site-pharmacology-impact-novel-treatment-development/2017-11-06T11:23:36+02:00https://staging.pauljanssenfuturelab.eu/topic/learning-objectives-explaining-pd-drug-body/2018-06-28T14:58:43+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-pharmacological-effects/2017-11-06T11:25:31+02:00https://staging.pauljanssenfuturelab.eu/topic/applying-methodology-different-types-interventions-2/2017-11-06T11:29:11+02:00https://staging.pauljanssenfuturelab.eu/topic/methodology-clinical-question-overview/2017-11-06T11:30:12+02:00https://staging.pauljanssenfuturelab.eu/topic/self-assessment-questions-article-5/2017-11-06T11:32:22+02:00https://staging.pauljanssenfuturelab.eu/topic/example-addressing-clinical-question-early-development/2017-11-06T11:33:37+02:00https://staging.pauljanssenfuturelab.eu/topic/clinical-endpoints-perspective-development-patient-doctors-regulatory-perspective/2017-11-06T11:34:29+02:00https://staging.pauljanssenfuturelab.eu/topic/self-assessment-question-article/2017-11-06T11:35:20+02:00https://staging.pauljanssenfuturelab.eu/topic/example-impact-clinical-specific-development-issue/2017-11-06T11:36:20+02:00https://staging.pauljanssenfuturelab.eu/topic/disease-state-animation-library/2017-11-06T11:37:49+02:00https://staging.pauljanssenfuturelab.eu/topic/signalling-disease-intervention-impact-novel-treatment-development/2017-11-06T11:38:31+02:00https://staging.pauljanssenfuturelab.eu/topic/learning-objectives-explaining-scope-topics-clinical-question/2017-11-06T11:39:57+02:00https://staging.pauljanssenfuturelab.eu/topic/case-example-clinical-effects/2017-11-06T11:40:50+02:00https://staging.pauljanssenfuturelab.eu/topic/applying-methodology-different-types-interventions-3/2017-11-06T11:48:18+02:00https://staging.pauljanssenfuturelab.eu/topic/methodolgy-window-question-overview/2017-11-06T11:49:05+02:00https://staging.pauljanssenfuturelab.eu/topic/exercise-ib-analyzer/2017-11-06T11:50:00+02:00https://staging.pauljanssenfuturelab.eu/topic/ib-analyzer-tutorial/2019-01-23T17:27:30+02:00https://staging.pauljanssenfuturelab.eu/topic/starting-dose-calculation-getting-right-dose/2019-01-23T17:18:17+02:00https://staging.pauljanssenfuturelab.eu/topic/defining-therapeutic-window-implications-novel-treatment-development/2017-11-06T11:52:34+02:00https://staging.pauljanssenfuturelab.eu/topic/self-assessment-questions-article-6/2017-11-06T11:53:34+02:00https://staging.pauljanssenfuturelab.eu/topic/example-impact-window-specific-development-issue-eg-small-thereutic-window/2017-11-06T11:54:32+02:00https://staging.pauljanssenfuturelab.eu/topic/adverse-drug-reactions-overview-mechanisms/2017-11-06T11:55:19+02:00https://staging.pauljanssenfuturelab.eu/topic/defining-therapeutic-window-implications-novel-treatment-development-2/2017-11-06T11:56:09+02:00https://staging.pauljanssenfuturelab.eu/topic/learning-objectives-explaining-scope-topics-window-question/2017-11-06T11:57:08+02:00https://staging.pauljanssenfuturelab.eu/topic/case-example-therapeutic-window/2017-11-06T11:58:01+02:00https://staging.pauljanssenfuturelab.eu/topic/link-qbcd-course-wrap/2017-11-06T12:07:44+02:00https://staging.pauljanssenfuturelab.eu/topic/prioritising-questions-introducing-question-based-development/2017-11-06T12:08:35+02:00https://staging.pauljanssenfuturelab.eu/topic/applying-methodology-different-types-interventions-4/2017-11-06T12:09:38+02:00https://staging.pauljanssenfuturelab.eu/topic/methodology-population-question-overview/2017-11-06T12:10:37+02:00https://staging.pauljanssenfuturelab.eu/topic/using-tpp-guidance-development/2017-11-06T12:11:36+02:00https://staging.pauljanssenfuturelab.eu/topic/defining-tpp-advance/2017-11-06T12:12:32+02:00https://staging.pauljanssenfuturelab.eu/topic/self-assessment-questions-article-7/2017-11-06T12:13:28+02:00https://staging.pauljanssenfuturelab.eu/topic/example-impact-population-specific-development-issue/2017-11-06T12:14:39+02:00https://staging.pauljanssenfuturelab.eu/topic/special-populations-overview-pediatrics-geriatrics-pregnancy-teratogenicity-ethnopharmacology/2017-11-06T12:15:23+02:00https://staging.pauljanssenfuturelab.eu/topic/defining-population-issues-implications-novel-treatment-development/2017-11-06T12:16:15+02:00https://staging.pauljanssenfuturelab.eu/topic/learning-objectives-explaining-scope-topics-population-question/2017-11-06T12:17:09+02:00https://staging.pauljanssenfuturelab.eu/topic/case-example-population-variability/2017-11-06T12:17:50+02:00https://staging.pauljanssenfuturelab.eu/topic/other-sections-in-the-patent-document/2020-09-04T15:33:22+02:00https://staging.pauljanssenfuturelab.eu/topic/building-blocks-patent-content/2019-02-13T18:05:42+02:00https://staging.pauljanssenfuturelab.eu/topic/two-criteria-define-scope-legislation/2021-05-26T10:59:49+02:00https://staging.pauljanssenfuturelab.eu/topic/experimental-treatment-versus-medical-scientific-research/2021-01-22T14:41:25+02:00https://staging.pauljanssenfuturelab.eu/topic/cryo-balloon-case-part-1/2021-01-22T14:42:38+02:00https://staging.pauljanssenfuturelab.eu/topic/cryo-balloon-case-part-2/2021-01-22T14:44:01+02:00https://staging.pauljanssenfuturelab.eu/topic/upcoming-themes-newsletter/2021-05-20T13:56:27+02:00https://staging.pauljanssenfuturelab.eu/topic/biobanks/2021-01-22T14:59:55+02:00https://staging.pauljanssenfuturelab.eu/topic/review-national-population-screening-research/2020-01-29T10:07:40+02:00https://staging.pauljanssenfuturelab.eu/topic/non-wmo-studies-involving-medicinal-products/2021-01-22T14:48:51+02:00https://staging.pauljanssenfuturelab.eu/topic/topic/2021-01-22T14:51:08+02:00https://staging.pauljanssenfuturelab.eu/topic/case-seeding-trial/2021-01-22T14:49:20+02:00https://staging.pauljanssenfuturelab.eu/topic/case-1-social-inhibition-emotional-distress-study/2021-01-22T14:52:52+02:00https://staging.pauljanssenfuturelab.eu/topic/case-1-really-happened/2021-01-22T14:55:18+02:00https://staging.pauljanssenfuturelab.eu/topic/case-2-study-effect-l-tyrosine-transcranial-direct-current-stimulation/2021-01-22T14:54:44+02:00https://staging.pauljanssenfuturelab.eu/topic/case-2-really-happened/2020-01-28T13:33:08+02:00https://staging.pauljanssenfuturelab.eu/topic/case-3-study-effects-oral-tyrosine-administration/2021-01-22T14:57:14+02:00https://staging.pauljanssenfuturelab.eu/topic/case-3-really-happened/2020-01-28T13:42:02+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-2/2018-03-08T17:13:02+02:00https://staging.pauljanssenfuturelab.eu/topic/wrap-up/2021-05-26T14:58:45+02:00https://staging.pauljanssenfuturelab.eu/topic/cryo-balloon-poll/2020-11-13T12:23:38+02:00https://staging.pauljanssenfuturelab.eu/topic/cryo-balloon-contd/2021-01-22T14:46:31+02:00https://staging.pauljanssenfuturelab.eu/topic/cryo-balloon-news-contd/2021-01-22T14:45:39+02:00https://staging.pauljanssenfuturelab.eu/topic/poll-advantage-trial/2020-05-26T16:22:24+02:00https://staging.pauljanssenfuturelab.eu/topic/the-front-page-of-a-patent-application/2021-12-14T16:11:40+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-claims-in-medical-life-sciences/2021-04-12T11:42:16+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-data-base-european-patent-register/2019-06-17T15:58:49+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-crispr-cas/2019-05-24T12:27:18+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-1/2019-05-28T09:03:03+02:00https://staging.pauljanssenfuturelab.eu/topic/week-1-learning-objectives-2/2021-11-10T15:05:11+02:00https://staging.pauljanssenfuturelab.eu/topic/week-4-learning-objectives-2/2021-12-06T09:57:22+02:00https://staging.pauljanssenfuturelab.eu/topic/futurelab-talk-eline-bunnik/2019-09-05T11:10:36+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-4/2018-05-16T16:23:58+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-5/2018-05-16T16:24:04+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-and-assignments/2021-02-25T10:28:55+02:00https://staging.pauljanssenfuturelab.eu/topic/program-7/2019-05-28T12:03:58+02:00https://staging.pauljanssenfuturelab.eu/topic/program-8/2019-04-19T12:27:28+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-and-assignments-2/2021-02-25T10:23:36+02:00https://staging.pauljanssenfuturelab.eu/topic/preparatory-assignment-gynocclude-qoc-analysis/2021-01-18T17:02:20+02:00https://staging.pauljanssenfuturelab.eu/topic/clin-obstet-gynecol-2006-uterine-artery-occlusion-what-is-the-evidence/2021-02-25T10:25:16+02:00https://staging.pauljanssenfuturelab.eu/topic/uterine-occlusion-movie-clip/2018-05-17T16:14:59+02:00https://staging.pauljanssenfuturelab.eu/topic/ib-splisomatics-haon51/2021-02-25T10:29:34+02:00https://staging.pauljanssenfuturelab.eu/topic/clin-exp-phar-and-phys-2006-antisense-oligonucluotides/2021-02-25T10:32:08+02:00https://staging.pauljanssenfuturelab.eu/topic/ema-2005-reflection-paper-on-the-assessment-of-the-genotoxicity-potential-of-antisense-oligonucleotides/2021-02-25T10:34:27+02:00https://staging.pauljanssenfuturelab.eu/topic/recap-introduction-to-patenting/2019-01-31T12:17:26+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-presentations/2019-05-01T13:15:27+02:00https://staging.pauljanssenfuturelab.eu/topic/case-study-presentation-really-happened/2018-07-02T14:43:04+02:00https://staging.pauljanssenfuturelab.eu/topic/attrition-rates-poll/2021-03-04T17:52:15+02:00https://staging.pauljanssenfuturelab.eu/topic/week-1-summary/2018-11-13T13:04:11+02:00https://staging.pauljanssenfuturelab.eu/topic/week-2-summary-2/2018-10-29T15:51:09+02:00https://staging.pauljanssenfuturelab.eu/topic/week-3-learning-objectives-3/2019-10-07T10:00:16+02:00https://staging.pauljanssenfuturelab.eu/topic/week-4-learning-objectives-3/2019-05-23T10:53:59+02:00https://staging.pauljanssenfuturelab.eu/topic/week-5-learning-objectives-3/2019-04-04T10:18:57+02:00https://staging.pauljanssenfuturelab.eu/topic/claiming-medical-methods-usa-europe/2019-02-14T17:38:46+02:00https://staging.pauljanssenfuturelab.eu/topic/exercise-galapagos-patents/2018-11-08T10:29:06+02:00https://staging.pauljanssenfuturelab.eu/topic/assignment-1b-analyzing-galapagos-key-eu-patent-filgotinib/2018-11-08T13:05:54+02:00https://staging.pauljanssenfuturelab.eu/topic/patenting-vs-publishing/2021-01-22T13:21:33+02:00https://staging.pauljanssenfuturelab.eu/topic/poll-freedom-to-operate/2018-11-20T17:19:26+02:00https://staging.pauljanssenfuturelab.eu/topic/mini-case-novelty-vs-prior-art/2018-11-20T17:23:12+02:00https://staging.pauljanssenfuturelab.eu/topic/learning-objectives-week-1/2019-02-05T14:08:21+02:00https://staging.pauljanssenfuturelab.eu/topic/poll-freedom-to-operate-2/2018-12-20T18:03:24+02:00https://staging.pauljanssenfuturelab.eu/topic/patentability-vs-freedom-to-operate/2019-06-21T14:10:43+02:00https://staging.pauljanssenfuturelab.eu/topic/exercise-familiarize-yourself-with-claims-drag-and-drop/2018-12-20T18:01:38+02:00https://staging.pauljanssenfuturelab.eu/topic/mini-case-embodiments-terugval-van-hoofd-naar-afhankelijke-claim/2019-02-13T18:16:26+02:00https://staging.pauljanssenfuturelab.eu/topic/parkeren/2019-02-06T17:30:17+02:00https://staging.pauljanssenfuturelab.eu/topic/4-types-of-ip-rights-opnemen-in-welcome-filmpje/2018-12-20T18:10:07+02:00https://staging.pauljanssenfuturelab.eu/topic/interview-with-bart-swinkels-2a-sufficient-disclosure-and-plausibility/2018-12-20T18:12:01+02:00https://staging.pauljanssenfuturelab.eu/topic/written-description-enablement/2019-01-31T12:21:41+02:00https://staging.pauljanssenfuturelab.eu/topic/interview-with-bart-swinkels-1c-biomedical-specific-aspects/2019-05-22T11:23:16+02:00https://staging.pauljanssenfuturelab.eu/topic/exercise-or-mini-case-swiss-type-claim-kees-gaat-iets-uitwerken/2019-02-07T16:49:20+02:00https://staging.pauljanssenfuturelab.eu/topic/mini-case-or-evergreening/2018-12-20T18:21:55+02:00https://staging.pauljanssenfuturelab.eu/topic/test/2019-01-10T17:37:55+02:00https://staging.pauljanssenfuturelab.eu/topic/critical-view-on-market-approval/2021-08-13T10:00:19+02:00https://staging.pauljanssenfuturelab.eu/topic/amgen-pcsk9-patents/2019-01-17T12:02:41+02:00https://staging.pauljanssenfuturelab.eu/topic/assignment-written-description/2019-01-17T17:21:48+02:00https://staging.pauljanssenfuturelab.eu/topic/assignment-written-description-2/2019-01-23T01:00:44+02:00https://staging.pauljanssenfuturelab.eu/topic/claiming-filgotinib-eu-patent/2019-01-30T15:11:32+02:00https://staging.pauljanssenfuturelab.eu/topic/patenting-human-genes-europe/2019-10-11T10:31:13+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-6/2019-02-06T11:21:03+02:00https://staging.pauljanssenfuturelab.eu/topic/mf-freedom-to-operate/2019-02-06T12:36:38+02:00https://staging.pauljanssenfuturelab.eu/topic/mini-case-pcsk9-inhibitor/2020-03-12T16:29:48+02:00https://staging.pauljanssenfuturelab.eu/topic/mini-case-4-filgotinib/2019-02-07T17:47:12+02:00https://staging.pauljanssenfuturelab.eu/topic/mini-case-4-filgotinib-2/2019-02-14T18:30:55+02:00https://staging.pauljanssenfuturelab.eu/topic/mini-case-claim-construction-detailed-patent-description-2/2019-02-13T18:16:39+02:00https://staging.pauljanssenfuturelab.eu/topic/mini-case-filgotinib/2019-10-15T11:19:06+02:00https://staging.pauljanssenfuturelab.eu/topic/11726/2019-03-07T15:12:17+02:00https://staging.pauljanssenfuturelab.eu/topic/11740/2019-03-07T15:13:41+02:00https://staging.pauljanssenfuturelab.eu/topic/program-9/2019-04-19T12:56:01+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-7/2019-04-19T13:51:25+02:00https://staging.pauljanssenfuturelab.eu/topic/program-10/2019-05-28T12:09:48+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-8/2019-04-24T11:51:57+02:00https://staging.pauljanssenfuturelab.eu/topic/preparatory-assignment-it53/2019-05-17T12:13:37+02:00https://staging.pauljanssenfuturelab.eu/topic/ema-guideline-clinical-investigation-medicinal-products-treatment-duchenne-becker-muscular-dystrophy/2021-02-25T10:31:29+02:00https://staging.pauljanssenfuturelab.eu/topic/preparatory-assignment-splisomatics/2019-05-17T12:19:17+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-9/2019-05-01T09:08:56+02:00https://staging.pauljanssenfuturelab.eu/topic/preparatory-assignment-somgenix-ltd/2019-05-17T12:24:08+02:00https://staging.pauljanssenfuturelab.eu/topic/teaching-case-somgenix-ltd/2021-02-25T10:46:16+02:00https://staging.pauljanssenfuturelab.eu/topic/somgenix-ltd-clinical-protocol/2021-02-25T10:47:04+02:00https://staging.pauljanssenfuturelab.eu/topic/ib-somgenix-ltd/2021-02-25T10:47:53+02:00https://staging.pauljanssenfuturelab.eu/topic/glybera-million-dollar-drug-access-crowe/2019-05-01T11:07:33+02:00https://staging.pauljanssenfuturelab.eu/topic/human-gene-therapy-commentary-glybera-story/2019-05-01T11:09:13+02:00https://staging.pauljanssenfuturelab.eu/topic/preparatory-assignment-bedaquiline/2019-05-17T12:21:54+02:00https://staging.pauljanssenfuturelab.eu/topic/short-video-message-paul-stoffels-cso-jj/2019-05-01T12:37:17+02:00https://staging.pauljanssenfuturelab.eu/topic/fda-guidance-for-industry-2005-estimating-maximum-safe-starting-dose/2021-02-25T10:39:23+02:00https://staging.pauljanssenfuturelab.eu/topic/developing-gynocclude-to-treat-uterine-fibroids/2021-02-25T10:24:35+02:00https://staging.pauljanssenfuturelab.eu/topic/reflection-paper-on-quality-non-clinical-and-clinical-issues-related-to-the-development-of-recombinant-adeno-associated-viral-vectors/2021-02-25T10:48:49+02:00https://staging.pauljanssenfuturelab.eu/topic/cbc-glybera-documentary/2019-05-02T12:56:55+02:00https://staging.pauljanssenfuturelab.eu/topic/from-mutation-identification-to-therapy-discovery-and-origins-of-the-first-approved-gene-therapy-in-the-western-world/2021-02-25T10:49:31+02:00https://staging.pauljanssenfuturelab.eu/topic/thalidomide-part-1/2019-11-25T13:55:06+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-10/2019-05-28T08:59:18+02:00https://staging.pauljanssenfuturelab.eu/topic/stakeholders-in-market-approval/2021-12-03T14:07:59+02:00https://staging.pauljanssenfuturelab.eu/topic/testpagina-bruno/2019-06-17T13:51:11+02:00https://staging.pauljanssenfuturelab.eu/topic/public-patent-application-information-retrieval-pair/2019-06-17T16:58:59+02:00https://staging.pauljanssenfuturelab.eu/topic/uspto-examination-route-of-the-broad-institute-key-stone-crispr-cas9-patent-application/2019-07-04T11:51:03+02:00https://staging.pauljanssenfuturelab.eu/topic/licensing-case-1-magnetic-impalpable-lesion-localisation/2019-10-03T15:56:57+02:00https://staging.pauljanssenfuturelab.eu/topic/poll-ethics/2019-08-26T13:51:29+02:00https://staging.pauljanssenfuturelab.eu/topic/eline-bunnik-ethics-and-autonomy-in-drug-regulation/2021-11-10T15:22:21+02:00https://staging.pauljanssenfuturelab.eu/topic/taking-a-more-critical-view/2021-11-19T10:01:46+02:00https://staging.pauljanssenfuturelab.eu/topic/sjaak-bot-begin-with-the-end-in-mind-but-what-is-the-end/2019-08-26T14:46:56+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-11/2019-08-26T15:05:32+02:00https://staging.pauljanssenfuturelab.eu/topic/licensing-case-2-nanobodies-for-diagnostic-and-therapeutic-applications/2019-10-03T16:55:22+02:00https://staging.pauljanssenfuturelab.eu/topic/mini-case-5-filgotinib-patent-granting-route-assignment/2019-09-19T15:24:01+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-12/2019-09-23T10:28:31+02:00https://staging.pauljanssenfuturelab.eu/topic/quiz-novelty-of-an-enantiomer/2019-10-02T11:18:02+02:00https://staging.pauljanssenfuturelab.eu/topic/take-home-messages/2019-10-09T16:19:42+02:00https://staging.pauljanssenfuturelab.eu/topic/mini-case-filgotinib-2/2019-10-17T16:15:46+02:00https://staging.pauljanssenfuturelab.eu/topic/how-to-use-the-patent-portfolio-calculator/2019-11-20T14:35:08+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-13/2019-12-10T17:51:51+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-14/2019-12-19T16:14:20+02:00https://staging.pauljanssenfuturelab.eu/topic/submitting-a-complete-and-well-structured-research-file/2021-05-26T11:49:25+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-3-the-abr-form-and-the-ccmo-national-register/2020-01-28T14:38:07+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ccmo-public-register/2020-01-28T16:00:00+02:00https://staging.pauljanssenfuturelab.eu/topic/studies-on-medicinal-products-with-human-subjects/2021-05-20T13:43:12+02:00https://staging.pauljanssenfuturelab.eu/topic/two-insurances/2021-05-20T13:46:51+02:00https://staging.pauljanssenfuturelab.eu/topic/data-safety-monitoring-committee/2021-01-22T15:06:29+02:00https://staging.pauljanssenfuturelab.eu/topic/legally-binding-review-timelines/2021-05-20T13:53:08+02:00https://staging.pauljanssenfuturelab.eu/topic/integrating-scientific-considerations-into-rd-project-valuation/2021-01-22T13:42:24+02:00https://staging.pauljanssenfuturelab.eu/topic/two-insurances-contd/2021-01-22T15:03:40+02:00https://staging.pauljanssenfuturelab.eu/topic/penalty-and-appeal-act/2020-01-28T17:30:49+02:00https://staging.pauljanssenfuturelab.eu/topic/injury-insurance-or-compensation-fund-for-dutch-research-subjects/2021-01-22T15:04:11+02:00https://staging.pauljanssenfuturelab.eu/topic/poll-injury-insurance-or-compensation-fund-for-dutch-research-subjects/2020-05-26T16:25:40+02:00https://staging.pauljanssenfuturelab.eu/topic/poll-medicinal-product-yes-or-no/2020-05-26T16:24:54+02:00https://staging.pauljanssenfuturelab.eu/topic/wrap-up-theme-2-the-mandatory-review-of-medical-research/2020-01-29T10:11:05+02:00https://staging.pauljanssenfuturelab.eu/topic/fto-questions-scenario-2/2020-05-27T09:25:04+02:00https://staging.pauljanssenfuturelab.eu/topic/indirect-patent-infringement-suing-the-supplier/2021-01-31T12:36:08+02:00https://staging.pauljanssenfuturelab.eu/topic/a-brief-history-of-market-approval/2021-11-10T15:06:30+02:00https://staging.pauljanssenfuturelab.eu/topic/a-brief-history-of-the-patent-system/2020-09-14T19:43:52+02:00https://staging.pauljanssenfuturelab.eu/topic/what-is-your-own-experience-with-ip/2020-09-14T19:44:50+02:00https://staging.pauljanssenfuturelab.eu/topic/bart-swinkels-part-1-patenting-your-intervention/2020-09-13T22:18:08+02:00https://staging.pauljanssenfuturelab.eu/topic/vib-and-prior-art/2021-01-11T17:12:35+02:00https://staging.pauljanssenfuturelab.eu/topic/vib-and-prior-art-find-a-solution/2021-04-12T11:17:39+02:00https://staging.pauljanssenfuturelab.eu/topic/vib-and-prior-art-what-really-happened/2020-10-02T13:50:48+02:00https://staging.pauljanssenfuturelab.eu/topic/claim-type-and-structure-1/2020-07-10T16:29:44+02:00https://staging.pauljanssenfuturelab.eu/topic/bart-swinkels-part-2-claims-and-embodiments/2020-09-04T15:34:13+02:00https://staging.pauljanssenfuturelab.eu/topic/claims-and-embodiments/2021-04-12T11:47:12+02:00https://staging.pauljanssenfuturelab.eu/topic/bart-swinkels-part-3-methods-of-treatment-and-second-medical-use-claims/2020-09-04T15:38:11+02:00https://staging.pauljanssenfuturelab.eu/topic/filgotinib-comparing-europe-and-the-us/2021-04-14T12:42:51+02:00https://staging.pauljanssenfuturelab.eu/topic/case-mayne-vs-msd-part-1/2021-12-14T16:59:02+02:00https://staging.pauljanssenfuturelab.eu/topic/case-mayne-vs-msd-part-2/2021-04-12T12:46:36+02:00https://staging.pauljanssenfuturelab.eu/topic/bart-swinkels-part-4-sufficient-disclosure-enablement-written-description-plausibility/2020-09-04T15:42:56+02:00https://staging.pauljanssenfuturelab.eu/topic/bart-swinkels-part-5-differences-between-europe-and-the-us-patenting-dna-sequences-and-antibodies/2020-09-17T18:54:27+02:00https://staging.pauljanssenfuturelab.eu/topic/wrap-up-week-1/2020-08-26T12:44:00+02:00https://staging.pauljanssenfuturelab.eu/topic/patenting-versus-publishing-poll/2021-04-12T11:15:08+02:00https://staging.pauljanssenfuturelab.eu/topic/case-mayne-vs-msd-part-1-contd/2020-08-27T09:28:10+02:00https://staging.pauljanssenfuturelab.eu/topic/case-mayne-vs-msd-part-2-1/2021-04-12T12:51:20+02:00https://staging.pauljanssenfuturelab.eu/topic/protecting-your-inventions-the-patent-system/2021-01-25T15:40:27+02:00https://staging.pauljanssenfuturelab.eu/topic/how-to-protect-an-invention-for-a-new-diagnostic-test/2020-10-26T10:16:27+02:00https://staging.pauljanssenfuturelab.eu/topic/interview-with-mrs-aliki-nichogiannopoulou-of-the-epo-part-1/2020-08-27T17:31:30+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-databases/2020-09-04T15:47:15+02:00https://staging.pauljanssenfuturelab.eu/topic/an-introduction-to-espacenet/2020-08-26T13:55:27+02:00https://staging.pauljanssenfuturelab.eu/topic/searching-for-patents-in-espacenet/2020-10-23T11:38:33+02:00https://staging.pauljanssenfuturelab.eu/topic/the-us-national-route/2020-11-12T23:20:16+02:00https://staging.pauljanssenfuturelab.eu/topic/the-us-national-route-and-new-claims/2020-09-02T16:54:11+02:00https://staging.pauljanssenfuturelab.eu/topic/claims-8-9-and-10-resolved/2020-08-30T11:15:39+02:00https://staging.pauljanssenfuturelab.eu/topic/the-pct-route-and-the-international-search-report/2020-08-26T13:09:06+02:00https://staging.pauljanssenfuturelab.eu/topic/the-european-regional-route/2020-10-23T13:50:34+02:00https://staging.pauljanssenfuturelab.eu/topic/interview-with-mrs-aliki-nichogiannopoulou-of-the-epo-part-2/2020-08-30T11:55:41+02:00https://staging.pauljanssenfuturelab.eu/topic/understanding-the-basics-of-patenting/2021-04-28T15:43:35+02:00https://staging.pauljanssenfuturelab.eu/topic/managing-the-costs-of-a-patent-portfolio/2020-08-30T12:06:39+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-portfolio-calculator/2021-04-14T10:52:15+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-portfolio-calculator-heartsnp/2020-10-23T13:47:03+02:00https://staging.pauljanssenfuturelab.eu/topic/exercise-2-patent-portfolio-calculator-a-medical-device-part-1/2020-10-26T20:38:33+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-portfolio-calculator-screening-compounds-using-a-cell-line/2020-10-26T22:12:01+02:00https://staging.pauljanssenfuturelab.eu/topic/interview-with-mrs-aliki-nichogiannopoulou-of-the-epo-part-3/2020-08-30T12:51:36+02:00https://staging.pauljanssenfuturelab.eu/topic/wrap-up-week-2/2020-08-26T13:15:29+02:00https://staging.pauljanssenfuturelab.eu/topic/understanding-the-isr-and-wo/2020-08-26T14:42:49+02:00https://staging.pauljanssenfuturelab.eu/topic/the-pct-route-and-the-written-opinion/2020-09-04T15:52:08+02:00https://staging.pauljanssenfuturelab.eu/topic/procedure-for-filing-and-obtaining-a-patent/2020-10-04T12:15:34+02:00https://staging.pauljanssenfuturelab.eu/topic/freedom-to-operate/2021-04-14T11:28:10+02:00https://staging.pauljanssenfuturelab.eu/topic/freedom-to-operate-part-1/2021-04-14T11:30:10+02:00https://staging.pauljanssenfuturelab.eu/topic/freedom-to-operate-part-2/2020-09-11T15:13:29+02:00https://staging.pauljanssenfuturelab.eu/topic/freedom-to-operate-part-3/2020-09-11T15:14:27+02:00https://staging.pauljanssenfuturelab.eu/topic/absolute-versus-relative-patent-protection/2021-04-14T11:35:14+02:00https://staging.pauljanssenfuturelab.eu/topic/exclusivity-a-single-term-with-many-meanings/2020-09-04T16:04:01+02:00https://staging.pauljanssenfuturelab.eu/topic/explaining-exclusivity/2021-01-27T15:18:53+02:00https://staging.pauljanssenfuturelab.eu/topic/interview-with-regulatory-specialist-marc-martens/2021-01-27T15:20:52+02:00https://staging.pauljanssenfuturelab.eu/topic/article-regarding-pediatric-exclusivity/2021-04-14T12:20:56+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-infringement-introduction/2020-09-04T16:09:15+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-patent-infringement/2020-09-09T22:57:19+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-infringement-car-t-cells-part-1/2020-09-11T15:06:02+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-infringement-car-t-cells-part-2/2020-09-11T15:15:05+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-infringement-car-t-cells-part-3/2021-01-27T15:38:33+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-infringement-car-t-cells-part-4/2020-09-11T15:17:40+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-infringement-car-t-cells-part-5/2020-09-11T15:18:12+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-infringement-car-t-cells-part-6/2020-09-11T15:18:58+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-infringement-car-t-cells-part-7/2020-09-11T15:19:25+02:00https://staging.pauljanssenfuturelab.eu/topic/indirect-patent-infringement-introduction/2020-09-04T16:15:10+02:00https://staging.pauljanssenfuturelab.eu/topic/the-clinimacs-prodigy-t-cell-transduction-process/2020-09-03T15:55:44+02:00https://staging.pauljanssenfuturelab.eu/topic/indirect-patent-infringement-allows-the-patentee-to-sue-suppliers-and-competitors-instead-of-customers/2021-01-31T12:45:20+02:00https://staging.pauljanssenfuturelab.eu/topic/clopidogrel-introduction/2020-09-04T16:17:32+02:00https://staging.pauljanssenfuturelab.eu/topic/clopidogrel-a-combination-of-two-ingredients/2020-09-10T16:13:17+02:00https://staging.pauljanssenfuturelab.eu/topic/clopidogrel-the-dispute-sanofi-versus-sandoz/2020-09-04T16:19:37+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-15/2020-09-03T13:07:05+02:00https://staging.pauljanssenfuturelab.eu/topic/clopidogrel-the-outcome-in-the-netherlands/2021-01-31T12:50:06+02:00https://staging.pauljanssenfuturelab.eu/topic/qa-session-with-bruno-marcel/2020-09-03T16:33:08+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-16/2020-09-03T13:09:11+02:00https://staging.pauljanssenfuturelab.eu/topic/wrap-up-week-3/2020-09-03T14:34:10+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-portfolio-calculator-screening-compounds-using-a-cell-line-answers/2020-09-03T13:56:09+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-infringement-conclusion/2020-09-11T15:12:28+02:00https://staging.pauljanssenfuturelab.eu/topic/clopidogrel-the-outcome-in-belgium/2020-09-04T16:21:06+02:00https://staging.pauljanssenfuturelab.eu/topic/framework-of-a-license-agreement/2021-08-10T14:20:11+02:00https://staging.pauljanssenfuturelab.eu/topic/the-various-degrees-of-technology-transfer-agreements/2021-01-22T13:28:09+02:00https://staging.pauljanssenfuturelab.eu/topic/test-your-knowledge-licensing/2020-09-16T16:35:24+02:00https://staging.pauljanssenfuturelab.eu/topic/grant-of-rights/2021-08-11T17:26:27+02:00https://staging.pauljanssenfuturelab.eu/topic/leveraging-your-intellectual-property-portfolio/2021-01-22T13:28:25+02:00https://staging.pauljanssenfuturelab.eu/topic/press-release-the-cross-license-between-avi-biopharma-and-eleos/2021-10-05T17:26:36+02:00https://staging.pauljanssenfuturelab.eu/topic/collaboration-between-gilead-and-galapagos/2021-04-23T11:36:42+02:00https://staging.pauljanssenfuturelab.eu/topic/the-gilead-galapagos-collaboration-agreement/2021-10-05T17:35:43+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ablynx-vs-unilever-dispute-part-1-the-facts-of-the-case-as-summarized-by-the-dutch-court/2021-08-03T10:18:46+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ablynx-vs-unilever-dispute-part-2-the-license-agreement-between-vub-and-unilever/2021-08-03T10:55:39+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ablynx-vs-unilever-dispute-part-3-the-source-of-the-contractual-dispute/2021-10-14T14:53:15+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ablynx-vs-unilever-dispute-part-4-the-response-from-unilever/2020-09-15T16:03:45+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ablynx-vs-unilever-dispute-part-4-food-or-medicinal-product/2020-09-28T17:32:50+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ablynx-vs-unilever-dispute-part-5-what-really-happened/2021-08-03T11:13:03+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ablynx-vs-unilever-dispute-part-6-hindsight-knowledge/2021-08-03T11:15:25+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ablynx-vs-unilever-dispute-part-7-finding-the-proper-dividing-line/2020-09-15T11:27:19+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ablynx-vs-unilever-dispute-part-8-analyze-the-courts-decision/2020-09-16T16:41:18+02:00https://staging.pauljanssenfuturelab.eu/topic/the-ablynx-vs-unilever-dispute-part-9-understanding-the-science-behind-the-dispute/2021-10-14T15:02:12+02:00https://staging.pauljanssenfuturelab.eu/topic/wrap-up-week-4/2020-09-04T13:20:12+02:00https://staging.pauljanssenfuturelab.eu/topic/licensing-in-biotech-collaborations/2021-05-10T11:52:28+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-infringement-car-t-cells-introduction/2020-09-11T11:21:16+02:00https://staging.pauljanssenfuturelab.eu/topic/direct-infringement-car-t-cells-introduction-2/2021-01-22T13:26:31+02:00https://staging.pauljanssenfuturelab.eu/topic/evaluation/2020-12-15T15:58:38+02:00https://staging.pauljanssenfuturelab.eu/topic/fto-questions-part-2/2020-09-24T17:14:50+02:00https://staging.pauljanssenfuturelab.eu/topic/fto-questions-part-4/2020-09-24T17:15:55+02:00https://staging.pauljanssenfuturelab.eu/topic/introduction-video-with-bruno/2020-09-25T10:43:31+02:00https://staging.pauljanssenfuturelab.eu/topic/case-1-%e2%80%92-the-pcsk9-inhibitor-case-what-is-sufficient-disclosure/2021-08-03T12:03:04+02:00https://staging.pauljanssenfuturelab.eu/topic/assignment/2021-08-03T12:04:58+02:00https://staging.pauljanssenfuturelab.eu/topic/what-really-happened/2021-08-03T12:13:11+02:00https://staging.pauljanssenfuturelab.eu/topic/case-2-%e2%80%92-escitalopram/2021-08-03T12:27:01+02:00https://staging.pauljanssenfuturelab.eu/topic/isolating-the-enantiomer/2021-02-28T12:27:50+02:00https://staging.pauljanssenfuturelab.eu/topic/the-court-disputes/2021-08-03T12:36:35+02:00https://staging.pauljanssenfuturelab.eu/topic/was-there-sufficient-disclosure/2020-09-30T16:33:31+02:00https://staging.pauljanssenfuturelab.eu/topic/inventive-step/2020-09-30T12:30:31+02:00https://staging.pauljanssenfuturelab.eu/topic/was-it-a-new-product/2021-08-03T12:54:47+02:00https://staging.pauljanssenfuturelab.eu/topic/summary-of-the-escitalopram-case/2020-09-30T17:01:24+02:00https://staging.pauljanssenfuturelab.eu/topic/patentability-of-biotechnological-inventions-in-europe/2020-10-02T13:55:44+02:00https://staging.pauljanssenfuturelab.eu/topic/the-per-c6-case-a-cell-line-for-the-production-of-gene-therapy-vectors/2020-10-02T13:55:04+02:00https://staging.pauljanssenfuturelab.eu/topic/new-applications-for-per-c6-cells/2021-01-22T13:31:53+02:00https://staging.pauljanssenfuturelab.eu/topic/the-per-c6-case-opposition/2020-09-25T10:24:42+02:00https://staging.pauljanssenfuturelab.eu/topic/opposition/2021-01-22T13:32:06+02:00https://staging.pauljanssenfuturelab.eu/topic/what-really-happened-2/2021-01-22T13:32:13+02:00https://staging.pauljanssenfuturelab.eu/topic/case-4-surgvision/2020-10-01T08:18:43+02:00https://staging.pauljanssenfuturelab.eu/topic/clinical-trials/2020-10-01T10:58:45+02:00https://staging.pauljanssenfuturelab.eu/topic/surgvisions-imaging-platform-and-its-intellectual-property-rights/2020-10-01T08:32:59+02:00https://staging.pauljanssenfuturelab.eu/topic/ipr-tools-for-protecting-surgvisions-imaging-platform/2020-09-30T12:34:50+02:00https://staging.pauljanssenfuturelab.eu/topic/analysis-of-surgvisions-cornerstone-patent/2020-10-02T10:38:44+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-examination-procedures-part-1/2020-10-02T10:35:26+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-examination-procedures-part-2/2020-10-01T10:53:25+02:00https://staging.pauljanssenfuturelab.eu/topic/patent-examination-procedures-part-3/2020-10-01T09:20:50+02:00https://staging.pauljanssenfuturelab.eu/topic/lessons-learned-looking-back-and-looking-forward/2020-10-02T13:57:45+02:00https://staging.pauljanssenfuturelab.eu/topic/licensing-exercise-based-on-surgvisions-fluorescent-marker-bevacizumab-irdye-800cw/2020-10-01T11:02:27+02:00https://staging.pauljanssenfuturelab.eu/topic/wrap-up-video-with-bruno/2020-11-27T15:57:21+02:00https://staging.pauljanssenfuturelab.eu/topic/assignment-2/2020-10-02T14:44:18+02:00https://staging.pauljanssenfuturelab.eu/topic/exercise-2-patent-portfolio-calculator-a-medical-device-part-2/2020-10-23T13:46:03+02:00https://staging.pauljanssenfuturelab.eu/topic/the-european-regional-route-part-1/2020-10-26T11:58:39+02:00https://staging.pauljanssenfuturelab.eu/topic/summary-week-1/2021-04-12T13:04:00+02:00https://staging.pauljanssenfuturelab.eu/topic/summary-week-2/2021-04-16T13:53:53+02:00https://staging.pauljanssenfuturelab.eu/topic/summary-week-3/2021-04-16T14:03:42+02:00https://staging.pauljanssenfuturelab.eu/topic/summary-week-4/2021-04-16T11:37:16+02:00https://staging.pauljanssenfuturelab.eu/topic/summary-week-5/2021-04-16T14:10:58+02:00https://staging.pauljanssenfuturelab.eu/topic/meet-galapagos-and-its-founder-onno-van-de-stolpe/2021-04-19T08:35:00+02:00https://staging.pauljanssenfuturelab.eu/topic/onno-van-de-stolpe-viewpoint/2021-12-14T17:21:45+02:00https://staging.pauljanssenfuturelab.eu/topic/onno-van-de-stolpe-process-of-obtaining-a-patent-and-the-interaction-with-a-patent-attorney/2021-04-22T15:04:43+02:00https://staging.pauljanssenfuturelab.eu/topic/onno-van-de-stolpe-background-and-reasons-gilead-galapagos-deal/2021-05-05T23:53:11+02:00https://staging.pauljanssenfuturelab.eu/topic/onno-van-de-stolpe-collaboration-between-gilead-and-galapagos/2021-05-05T23:58:59+02:00https://staging.pauljanssenfuturelab.eu/topic/onno-van-de-stolpe-its-all-about-the-deal/2021-05-05T14:09:03+02:00https://staging.pauljanssenfuturelab.eu/topic/onno-van-de-stolpe-having-the-right-skillset-for-making-a-deal/2021-10-05T16:56:14+02:00https://staging.pauljanssenfuturelab.eu/topic/onno-van-de-stolpe-no-deals-without-a-vision/2021-05-05T14:16:55+02:00https://staging.pauljanssenfuturelab.eu/topic/melatonin-a-medical-product-with-many-faces/2021-11-18T13:00:25+02:00https://staging.pauljanssenfuturelab.eu/topic/covid-19-patents-during-the-pandemic/2021-05-14T13:06:24+02:00https://staging.pauljanssenfuturelab.eu/topic/poll-qualified-members/2021-05-26T15:02:36+02:00https://staging.pauljanssenfuturelab.eu/topic/grant-of-rights-background-reading/2021-08-11T17:26:34+02:00https://staging.pauljanssenfuturelab.eu/topic/personal-introduction/2021-12-03T14:12:11+02:00https://staging.pauljanssenfuturelab.eu/topic/clinical-trials-and-informed-consent/2021-11-10T15:21:25+02:00https://staging.pauljanssenfuturelab.eu/topic/the-informed-consent-process/2021-11-10T15:17:35+02:00https://staging.pauljanssenfuturelab.eu/topic/compassionate-use-and-right-to-try/2021-12-03T14:09:39+02:00https://staging.pauljanssenfuturelab.eu/topic/the-benefit-risk-ratio/2021-12-03T14:10:31+02:00https://staging.pauljanssenfuturelab.eu/topic/the-benefit-risk-ratio-for-novel-anticoagulants/2021-11-18T13:17:48+02:00https://staging.pauljanssenfuturelab.eu/topic/regulatory-assessment-criteria/2021-11-18T12:56:35+02:00https://staging.pauljanssenfuturelab.eu/topic/bedaquiline-for-mdr-tuberculosis-the-fda-advisory-committee/2021-11-10T15:27:56+02:00https://staging.pauljanssenfuturelab.eu/topic/bedaquiline-for-mdr-tb-welcome-to-the-fda-aidac-meeting/2021-11-10T15:29:30+02:00https://staging.pauljanssenfuturelab.eu/topic/bedaquiline-for-mdr-tb-audio-from-the-fda-anti-infective-drugs-advisory-committee-aidac-meeting/2021-11-10T15:31:08+02:00https://staging.pauljanssenfuturelab.eu/topic/bedaquiline-for-mdr-tb-outcome-of-the-vote/2021-11-10T15:34:37+02:00https://staging.pauljanssenfuturelab.eu/topic/bedaquiline-for-mdr-tb-the-aidacs-opinions/2021-11-10T15:38:16+02:00https://staging.pauljanssenfuturelab.eu/topic/bedaquiline-for-mdr-tb-did-the-ema-reach-the-same-conclusion-regarding-the-benefit-risk-ratio/2021-11-24T09:40:55+02:00https://staging.pauljanssenfuturelab.eu/topic/week-1-summary-2/2021-11-10T15:42:50+02:00https://staging.pauljanssenfuturelab.eu/topic/week-1-wrap-up/2021-11-10T15:43:12+02:00https://staging.pauljanssenfuturelab.eu/topic/melatonin-assessment/2021-11-24T09:59:36+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-3/2021-08-13T12:53:09+02:00https://staging.pauljanssenfuturelab.eu/topic/bedaquiline-for-mdr-tb-the-vote-question-1/2021-11-10T15:31:33+02:00https://staging.pauljanssenfuturelab.eu/topic/bedaquiline-for-mdr-tb-the-vote-question-2/2021-11-10T15:32:01+02:00https://staging.pauljanssenfuturelab.eu/topic/week-2-learning-objectives-2/2021-11-22T10:51:51+02:00https://staging.pauljanssenfuturelab.eu/topic/claims/2021-11-24T15:07:11+02:00https://staging.pauljanssenfuturelab.eu/topic/claim-evidence-and-reasoning/2021-11-22T10:52:47+02:00https://staging.pauljanssenfuturelab.eu/topic/claim-evidence-and-reasoning-contd/2021-11-26T16:31:59+02:00https://staging.pauljanssenfuturelab.eu/topic/label-claim-off-label-use/2021-11-22T10:54:01+02:00https://staging.pauljanssenfuturelab.eu/topic/label-claim-off-label-use-self-assessment/2023-04-06T16:35:56+02:00https://staging.pauljanssenfuturelab.eu/topic/the-claimed-indication/2021-11-22T13:59:38+02:00https://staging.pauljanssenfuturelab.eu/topic/indication-for-bedaquiline/2021-11-26T16:33:53+02:00https://staging.pauljanssenfuturelab.eu/topic/a-new-indication-for-bedaquiline/2021-11-26T16:34:51+02:00https://staging.pauljanssenfuturelab.eu/topic/bedaquiline-exercise-completing-the-tpp/2021-11-24T11:45:04+02:00https://staging.pauljanssenfuturelab.eu/topic/target-product-profile-for-bedaquiline-sirturo-other-topics/2021-11-24T10:11:59+02:00https://staging.pauljanssenfuturelab.eu/topic/applying-the-tpp-in-product-development/2021-11-22T11:00:59+02:00https://staging.pauljanssenfuturelab.eu/topic/futurelab-talk-by-henk-schuring-developing-medicinal-products-for-orphan-diseases/2021-11-22T11:02:27+02:00https://staging.pauljanssenfuturelab.eu/topic/a-new-dose-for-eliglustat-cerdelga-evidence/2021-11-22T11:02:51+02:00https://staging.pauljanssenfuturelab.eu/topic/genzyme-and-eliglustat-reading-and-assignment/2021-11-24T14:27:06+02:00https://staging.pauljanssenfuturelab.eu/topic/genzyme-and-eliglustat/2021-11-22T11:04:21+02:00https://staging.pauljanssenfuturelab.eu/topic/the-role-of-the-regulatory-affairs-expert-in-the-project-team/2021-11-22T11:04:44+02:00https://staging.pauljanssenfuturelab.eu/topic/mission-impossible/2021-11-22T11:05:06+02:00https://staging.pauljanssenfuturelab.eu/topic/the-million-dollar-drug-that-patients-cant-access/2021-11-22T11:05:37+02:00https://staging.pauljanssenfuturelab.eu/topic/quegen-the-development-of-lipidagen/2021-11-22T11:06:07+02:00https://staging.pauljanssenfuturelab.eu/topic/quegen-regulatory-history/2021-11-26T16:38:53+02:00https://staging.pauljanssenfuturelab.eu/topic/reflect-on-your-own-case/2021-11-22T11:08:32+02:00https://staging.pauljanssenfuturelab.eu/topic/week-2-summary/2021-11-22T11:08:52+02:00https://staging.pauljanssenfuturelab.eu/topic/week-2-wrap-up/2021-11-22T11:09:14+02:00https://staging.pauljanssenfuturelab.eu/topic/quegen-the-development-of-lipidagen-contd-3/2021-11-22T11:07:35+02:00https://staging.pauljanssenfuturelab.eu/topic/quegen-the-development-of-lipidagen-contd-2/2021-11-26T16:37:54+02:00https://staging.pauljanssenfuturelab.eu/topic/week-3-learning-objectives-2/2021-11-29T10:33:34+02:00https://staging.pauljanssenfuturelab.eu/topic/thalidomide/2021-11-29T10:41:16+02:00https://staging.pauljanssenfuturelab.eu/topic/legislation/2021-11-29T10:56:14+02:00https://staging.pauljanssenfuturelab.eu/topic/prof-bernd-van-der-meulen-on-the-interface-between-food-and-medicine/2021-11-29T10:59:10+02:00https://staging.pauljanssenfuturelab.eu/topic/personal-example-of-product-classification/2021-11-29T11:01:06+02:00https://staging.pauljanssenfuturelab.eu/topic/the-drug-eluting-stent-%e2%80%92-a-medical-device-medicinal-product-or-both/2021-11-29T11:02:14+02:00https://staging.pauljanssenfuturelab.eu/topic/classification/2021-11-29T11:03:15+02:00https://staging.pauljanssenfuturelab.eu/topic/guidelines/2021-11-29T11:06:51+02:00https://staging.pauljanssenfuturelab.eu/topic/finding-and-reading-a-guideline/2021-12-03T14:21:40+02:00https://staging.pauljanssenfuturelab.eu/topic/find-a-guideline-using-key-words-the-classic-approach/2021-11-29T11:21:20+02:00https://staging.pauljanssenfuturelab.eu/topic/find-a-guideline-using-key-words-the-classic-approach-contd/2021-11-29T11:22:06+02:00https://staging.pauljanssenfuturelab.eu/topic/find-a-guideline-by-topic-the-classic-approach/2021-11-29T11:24:00+02:00https://staging.pauljanssenfuturelab.eu/topic/find-a-guideline-using-the-market-approval-navigator-man/2023-03-16T16:56:18+02:00https://staging.pauljanssenfuturelab.eu/topic/find-a-guideline-regarding-long-term-follow-up/2021-11-29T11:26:25+02:00https://staging.pauljanssenfuturelab.eu/topic/find-a-guideline-%e2%80%92-your-own-example/2021-11-29T11:27:35+02:00https://staging.pauljanssenfuturelab.eu/topic/introduction-to-the-registration-dossier/2021-11-29T11:29:40+02:00https://staging.pauljanssenfuturelab.eu/topic/rb3285-impd-gap-analysis-the-quality-part-of-the-impd/2021-11-29T11:36:20+02:00https://staging.pauljanssenfuturelab.eu/topic/specifications/2021-11-29T11:38:43+02:00https://staging.pauljanssenfuturelab.eu/topic/specifications-contd/2021-11-26T12:46:33+02:00https://staging.pauljanssenfuturelab.eu/topic/introduction-to-impurities/2021-11-29T11:50:13+02:00https://staging.pauljanssenfuturelab.eu/topic/residual-solvents/2021-11-26T14:40:25+02:00https://staging.pauljanssenfuturelab.eu/topic/residual-solvent-classes/2021-11-29T11:54:57+02:00https://staging.pauljanssenfuturelab.eu/topic/residual-solvent-specifications-for-rb3285/2021-11-29T12:01:04+02:00https://staging.pauljanssenfuturelab.eu/topic/batch-analysis-data-for-rb3285/2021-11-29T12:04:35+02:00https://staging.pauljanssenfuturelab.eu/topic/justification-for-the-out-of-specification-results-for-rb3285/2021-11-29T12:05:05+02:00https://staging.pauljanssenfuturelab.eu/topic/advice-to-the-company-management-regarding-the-residual-solvents-in-rb3285/2021-11-29T12:05:32+02:00https://staging.pauljanssenfuturelab.eu/topic/related-substances/2021-11-29T12:06:05+02:00https://staging.pauljanssenfuturelab.eu/topic/find-the-applicable-guideline-related-substances/2021-11-29T12:07:10+02:00https://staging.pauljanssenfuturelab.eu/topic/related-substance-specifications/2021-11-29T12:08:22+02:00https://staging.pauljanssenfuturelab.eu/topic/related-substance-thresholds-for-rb3285/2021-11-29T12:08:52+02:00https://staging.pauljanssenfuturelab.eu/topic/related-substance-specifications-for-rb3285/2021-11-29T12:13:55+02:00https://staging.pauljanssenfuturelab.eu/topic/justification-of-specifications-for-rb3285/2021-11-29T12:15:49+02:00https://staging.pauljanssenfuturelab.eu/topic/batch-analysis-data-for-the-rb3285-drug-substance/2021-11-29T12:16:43+02:00https://staging.pauljanssenfuturelab.eu/topic/batch-analysis-data-for-the-rb3285-drug-product/2021-11-29T12:17:20+02:00https://staging.pauljanssenfuturelab.eu/topic/comparison-of-the-related-substance-profiles-between-rb3285-drug-substance-and-drug-product-batches/2021-11-29T12:17:46+02:00https://staging.pauljanssenfuturelab.eu/topic/degradation-products-in-rb3285/2021-11-29T12:18:15+02:00https://staging.pauljanssenfuturelab.eu/topic/your-advice-to-your-company-regarding-related-substances-in-rb3285/2021-11-29T12:19:40+02:00https://staging.pauljanssenfuturelab.eu/topic/rb3285-impd-gap-analysis-the-nonclinical-part-of-the-impd/2021-11-29T12:25:15+02:00https://staging.pauljanssenfuturelab.eu/topic/route-of-administration-for-rb3285/2021-11-29T12:25:46+02:00https://staging.pauljanssenfuturelab.eu/topic/nonclinical-studies-required-by-ich-guideline-m3/2021-11-26T17:30:02+02:00https://staging.pauljanssenfuturelab.eu/topic/change-of-indication-for-rb3285/2021-11-29T12:30:04+02:00https://staging.pauljanssenfuturelab.eu/topic/local-tolerance-studies-for-intrathecal-injection/2021-11-29T12:29:45+02:00https://staging.pauljanssenfuturelab.eu/topic/carcinogenicity/2021-11-29T12:30:25+02:00https://staging.pauljanssenfuturelab.eu/topic/advice-to-your-company-regarding-the-nonclinical-data-package-for-rb3285/2021-11-29T12:30:47+02:00https://staging.pauljanssenfuturelab.eu/topic/advice-to-yourself/2021-11-29T12:31:09+02:00https://staging.pauljanssenfuturelab.eu/topic/rb3285-clinical/2021-11-29T12:31:28+02:00https://staging.pauljanssenfuturelab.eu/topic/week-3-summary-2/2021-11-29T12:32:04+02:00https://staging.pauljanssenfuturelab.eu/topic/week-3-wrap-up/2021-11-29T12:32:24+02:00https://staging.pauljanssenfuturelab.eu/topic/quegen-the-development-of-lipidagen-contd/2021-11-26T16:36:36+02:00https://staging.pauljanssenfuturelab.eu/topic/ma-model/2021-09-08T15:53:00+02:00https://staging.pauljanssenfuturelab.eu/topic/week-1-feedback/2021-09-17T11:17:30+02:00https://staging.pauljanssenfuturelab.eu/topic/game-plan-for-authority-consultation/2021-12-06T10:23:51+02:00https://staging.pauljanssenfuturelab.eu/topic/relationship-between-authority-consultation-and-the-size-of-the-company/2021-12-06T10:48:42+02:00https://staging.pauljanssenfuturelab.eu/topic/requesting-authority-consultation/2021-12-06T10:06:43+02:00https://staging.pauljanssenfuturelab.eu/topic/the-timing-of-authority-consultation/2021-12-06T10:07:11+02:00https://staging.pauljanssenfuturelab.eu/topic/unmet-medical-need-and-accelerated-approval-pathways/2021-12-06T10:49:38+02:00https://staging.pauljanssenfuturelab.eu/topic/the-timing-of-authority-consultation-2/2021-12-06T10:50:44+02:00https://staging.pauljanssenfuturelab.eu/topic/how-to-phrase-a-question/2021-12-06T10:51:14+02:00https://staging.pauljanssenfuturelab.eu/topic/how-to-phrase-a-question-to-the-regulatory-authority/2021-12-06T10:51:59+02:00https://staging.pauljanssenfuturelab.eu/topic/the-company-position-part-1/2021-12-06T10:52:46+02:00https://staging.pauljanssenfuturelab.eu/topic/the-company-position-part-2/2021-12-06T10:53:22+02:00https://staging.pauljanssenfuturelab.eu/topic/introduction-to-pediatric-development-programs/2021-12-06T10:54:10+02:00https://staging.pauljanssenfuturelab.eu/topic/authority-consultation-for-spostare-therapeutics-for-their-serotonin-receptor-agonist-savaxopride/2021-12-06T10:55:59+02:00https://staging.pauljanssenfuturelab.eu/topic/authority-consultation-for-spostare-therapeutics-for-their-serotonin-receptor-agonist-savaxopride-contd/2021-12-06T10:58:22+02:00https://staging.pauljanssenfuturelab.eu/topic/the-briefing-package/2021-12-06T10:59:10+02:00https://staging.pauljanssenfuturelab.eu/topic/stakeholders-in-preparing-for-authority-consultation/2021-12-06T10:59:33+02:00https://staging.pauljanssenfuturelab.eu/topic/preparation-for-an-authority-consultation-meeting/2023-10-17T15:34:50+02:00https://staging.pauljanssenfuturelab.eu/topic/spiros-vamvakas-part-2-lessons-learned/2021-12-06T11:01:42+02:00https://staging.pauljanssenfuturelab.eu/topic/negotiation-and-communication/2021-12-06T11:02:15+02:00https://staging.pauljanssenfuturelab.eu/topic/negotiation-and-communication-genentech-in-1987/2021-12-06T11:03:25+02:00https://staging.pauljanssenfuturelab.eu/topic/negotiation-and-communication-genentech-in-1987-epilogue/2021-12-06T11:04:57+02:00https://staging.pauljanssenfuturelab.eu/topic/the-meeting-minutes/2021-12-06T11:05:46+02:00https://staging.pauljanssenfuturelab.eu/topic/incorporating-feedback/2021-12-06T11:08:42+02:00https://staging.pauljanssenfuturelab.eu/topic/onno-van-de-stolpe-ceo-at-galapagos/2021-12-06T11:07:25+02:00https://staging.pauljanssenfuturelab.eu/topic/week-4-summary-2/2021-12-06T11:09:34+02:00https://staging.pauljanssenfuturelab.eu/topic/week-4-wrap-up/2021-12-06T11:09:56+02:00https://staging.pauljanssenfuturelab.eu/topic/week-5-learning-objectives-2/2021-12-17T11:31:50+02:00https://staging.pauljanssenfuturelab.eu/topic/thalidomide-2/2021-12-17T11:32:11+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-17/2021-09-21T09:16:12+02:00https://staging.pauljanssenfuturelab.eu/topic/life-long-monitoring-of-the-benefit-risk-ratio/2021-12-17T11:32:35+02:00https://staging.pauljanssenfuturelab.eu/topic/begin-with-the-end-in-mind/2021-12-17T11:33:18+02:00https://staging.pauljanssenfuturelab.eu/topic/pharmacovigilance-risk-management/2021-12-17T11:33:42+02:00https://staging.pauljanssenfuturelab.eu/topic/back-to-the-vioxx-case-kill-the-drug-in-time/2021-12-17T11:34:20+02:00https://staging.pauljanssenfuturelab.eu/topic/learning-lessons-from-pfizers-800-million-failure/2021-12-17T11:35:00+02:00https://staging.pauljanssenfuturelab.eu/topic/b-r-of-cetp-inhibitors/2021-12-17T11:35:20+02:00https://staging.pauljanssenfuturelab.eu/topic/life-long-positive-b-r-in-healthy-subjects/2021-12-17T11:35:51+02:00https://staging.pauljanssenfuturelab.eu/topic/the-impact-of-therapy-incompliance/2021-12-17T11:37:16+02:00https://staging.pauljanssenfuturelab.eu/topic/covid-19-vaccines/2021-12-17T11:38:02+02:00https://staging.pauljanssenfuturelab.eu/topic/covid-vaccine-vaxzevria-b-r-at-clinical-development/2021-12-17T11:38:38+02:00https://staging.pauljanssenfuturelab.eu/topic/covid-vaccine-vaxzevria-b-r-at-clinical-manufacturing/2021-12-17T11:40:06+02:00https://staging.pauljanssenfuturelab.eu/topic/astrazenecas-communication-on-clinical-manufacturing/2021-12-17T11:41:21+02:00https://staging.pauljanssenfuturelab.eu/topic/covid-vaccine-vaxzevria-b-r-at-market-approval/2021-12-17T11:42:45+02:00https://staging.pauljanssenfuturelab.eu/topic/covid-vaccine-vaxzevria-b-r-at-market-approval-contd/2021-12-17T11:44:37+02:00https://staging.pauljanssenfuturelab.eu/topic/communicating-b-r-to-the-general-public/2021-12-17T11:48:03+02:00https://staging.pauljanssenfuturelab.eu/topic/futurelab-talk-bert-leufkens/2021-12-17T11:49:30+02:00https://staging.pauljanssenfuturelab.eu/topic/tolerability-of-risk/2021-12-17T11:51:18+02:00https://staging.pauljanssenfuturelab.eu/topic/the-toolkit-of-the-authorities-to-manage-b-r/2021-12-17T11:51:59+02:00https://staging.pauljanssenfuturelab.eu/topic/special-regulatory-designations-and-approval-routes/2021-12-17T11:52:23+02:00https://staging.pauljanssenfuturelab.eu/topic/special-regulatory-designations-and-approval-routes-biogen/2021-12-17T11:57:13+02:00https://staging.pauljanssenfuturelab.eu/topic/development-of-a-sars-cov2-vaccine/2021-12-17T12:10:38+02:00https://staging.pauljanssenfuturelab.eu/topic/development-of-a-sars-cov2-vaccine-2/2021-12-17T12:11:11+02:00https://staging.pauljanssenfuturelab.eu/topic/market-approval-strategy/2021-12-17T12:11:42+02:00https://staging.pauljanssenfuturelab.eu/topic/public-assessment-reports/2021-12-17T12:13:57+02:00https://staging.pauljanssenfuturelab.eu/topic/week-5-summary-2/2021-12-17T12:15:28+02:00https://staging.pauljanssenfuturelab.eu/topic/week-5-closing-remarks/2021-12-17T12:16:06+02:00https://staging.pauljanssenfuturelab.eu/topic/building-a-license-agreement-assignment-1/2021-10-27T09:46:15+02:00https://staging.pauljanssenfuturelab.eu/topic/building-a-license-agreement-assignment-2/2021-10-27T09:48:01+02:00https://staging.pauljanssenfuturelab.eu/topic/building-a-license-agreement-assignment-3/2021-10-27T09:50:43+02:00https://staging.pauljanssenfuturelab.eu/topic/building-a-license-agreement-assignment-4/2021-10-27T09:52:14+02:00https://staging.pauljanssenfuturelab.eu/topic/building-a-license-agreement-assignment-5/2021-10-27T09:53:41+02:00https://staging.pauljanssenfuturelab.eu/topic/building-a-license-agreement-assignment-6/2021-10-27T09:56:02+02:00https://staging.pauljanssenfuturelab.eu/topic/building-a-license-agreement-assignment-7/2021-10-27T09:57:06+02:00https://staging.pauljanssenfuturelab.eu/topic/building-a-license-agreement-assignment-8/2021-10-27T09:58:12+02:00https://staging.pauljanssenfuturelab.eu/topic/week-2-feedback/2021-09-27T10:05:11+02:00https://staging.pauljanssenfuturelab.eu/topic/target-product-profile-tpp-a-strategic-tool/2021-11-22T10:58:31+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-18/2021-09-27T10:37:55+02:00https://staging.pauljanssenfuturelab.eu/topic/a-new-dose-for-eliglistat-cerdelga-reasoning/2021-11-22T11:03:23+02:00https://staging.pauljanssenfuturelab.eu/topic/building-a-license-agreement-what-really-happened-the-genentech-case/2021-10-28T11:34:06+02:00https://staging.pauljanssenfuturelab.eu/topic/week-3-feedback/2021-09-30T14:49:01+02:00https://staging.pauljanssenfuturelab.eu/topic/week-4-feedback/2021-10-06T15:44:05+02:00https://staging.pauljanssenfuturelab.eu/topic/authority-consultation-does-it-always-help/2021-12-06T10:04:29+02:00https://staging.pauljanssenfuturelab.eu/topic/kill-the-drug-in-time-part-2/2021-12-17T11:34:39+02:00https://staging.pauljanssenfuturelab.eu/topic/the-vaxzevria-covid-19-vaccine-what-really-happened/2021-12-17T11:40:53+02:00https://staging.pauljanssenfuturelab.eu/topic/alumni/2021-10-14T17:06:14+02:00https://staging.pauljanssenfuturelab.eu/topic/alumni-cd/2021-10-14T17:10:15+02:00https://staging.pauljanssenfuturelab.eu/topic/a-final-view-on-market-approval/2021-12-17T12:14:58+02:00https://staging.pauljanssenfuturelab.eu/topic/week-5-feedback/2021-10-18T13:11:18+02:00https://staging.pauljanssenfuturelab.eu/topic/human-tissue-plasminogen-activator-t-pa-contd/2021-10-27T11:01:51+02:00https://staging.pauljanssenfuturelab.eu/topic/course-evaluation/2021-12-17T12:17:41+02:00https://staging.pauljanssenfuturelab.eu/topic/online-exam-clinical-development-online/2021-12-15T18:14:37+02:00https://staging.pauljanssenfuturelab.eu/topic/test-topic-1-2/2023-03-03T16:04:17+02:00https://staging.pauljanssenfuturelab.eu/topic/test-topic-2-2/2023-03-09T14:22:47+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-1-2/2023-10-10T15:12:19+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-2-2/2023-10-19T13:46:32+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-1-3/2023-03-24T15:45:20+02:00https://staging.pauljanssenfuturelab.eu/topic/topic-2-3/2023-10-19T12:59:39+02:00https://staging.pauljanssenfuturelab.eu/topic/wat-je-moet-weten-t/2023-10-19T12:15:24+02:00